Literature DB >> 24567410

Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.

Takayuki Hoshii1, Atsuo Kasada, Tomoki Hatakeyama, Masashi Ohtani, Yuko Tadokoro, Kazuhito Naka, Tsuneo Ikenoue, Tomokatsu Ikawa, Hiroshi Kawamoto, Hans Joerg Fehling, Kimi Araki, Ken-ichi Yamamura, Satoshi Matsuda, Atsushi Hirao.   

Abstract

mTOR is an evolutionarily conserved kinase that plays a critical role in sensing and responding to environmental determinants. Recent studies have shown that fine-tuning of the activity of mTOR complexes contributes to organogenesis and tumorigenesis. Although rapamycin, an allosteric mTOR inhibitor, is an effective immunosuppressant, the precise roles of mTOR complexes in early T-cell development remain unclear. Here we show that mTORC1 plays a critical role in the development of both early T-cell progenitors and leukemia. Deletion of Raptor, an essential component of mTORC1, produced defects in the earliest development of T-cell progenitors in vivo and in vitro. Deficiency of Raptor resulted in cell cycle abnormalities in early T-cell progenitors that were associated with instability of the Cyclin D2/D3-CDK6 complexes; deficiency of Rictor, an mTORC2 component, did not have the same effect, indicating that mTORC1 and -2 control T-cell development in different ways. In a model of myeloproliferative neoplasm and T-cell acute lymphoblastic leukemia (T-ALL) evoked by Kras activation, Raptor deficiency dramatically inhibited the cell cycle in oncogenic Kras-expressing T-cell progenitors, but not myeloid progenitors, and specifically prevented the development of T-ALL. Although rapamycin treatment significantly prolonged the survival of recipient mice bearing T-ALL cells, rapamycin-insensitive leukemia cells continued to propagate in vivo. In contrast, Raptor deficiency in the T-ALL model resulted in cell cycle arrest and efficient eradication of leukemia. Thus, understanding the cell-context-dependent role of mTORC1 illustrates the potential importance of mTOR signals as therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24567410      PMCID: PMC3956177          DOI: 10.1073/pnas.1320265111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention.

Authors:  Jiwang Zhang; Justin C Grindley; Tong Yin; Sachintha Jayasinghe; Xi C He; Jason T Ross; Jeffrey S Haug; Dawn Rupp; Kimberly S Porter-Westpfahl; Leanne M Wiedemann; Hong Wu; Linheng Li
Journal:  Nature       Date:  2006-04-23       Impact factor: 49.962

2.  Polycomb group gene mel-18 regulates early T progenitor expansion by maintaining the expression of Hes-1, a target of the Notch pathway.

Authors:  Masaki Miyazaki; Hiroshi Kawamoto; Yuko Kato; Manami Itoi; Kazuko Miyazaki; Kyoko Masuda; Satoshi Tashiro; Hiroto Ishihara; Kazuhiko Igarashi; Takashi Amagai; Rieko Kanno; Masamoto Kanno
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

3.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.

Authors:  Guo Wei; David Twomey; Justin Lamb; Krysta Schlis; Jyoti Agarwal; Ronald W Stam; Joseph T Opferman; Stephen E Sallan; Monique L den Boer; Rob Pieters; Todd R Golub; Scott A Armstrong
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

4.  Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.

Authors:  Pilar García-Morales; Eva Hernando; Estefanía Carrasco-García; María Piedad Menéndez-Gutierrez; Miguel Saceda; Isabel Martínez-Lacaci
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

5.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

Authors:  Omer H Yilmaz; Riccardo Valdez; Brian K Theisen; Wei Guo; David O Ferguson; Hong Wu; Sean J Morrison
Journal:  Nature       Date:  2006-04-05       Impact factor: 49.962

6.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

7.  Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.

Authors:  Li Ma; Zhenbang Chen; Hediye Erdjument-Bromage; Paul Tempst; Pier Paolo Pandolfi
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

8.  The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines.

Authors:  S Kawamata; H Sakaida; T Hori; M Maeda; T Uchiyama
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

9.  The effect of rapamycin on T cell development in mice.

Authors:  H Luo; W Duguid; H Chen; M Maheu; J Wu
Journal:  Eur J Immunol       Date:  1994-03       Impact factor: 5.532

10.  Requirement for cyclin D3 in lymphocyte development and T cell leukemias.

Authors:  Ewa Sicinska; Iannis Aifantis; Laurent Le Cam; Wojciech Swat; Christine Borowski; Qunyan Yu; Adolfo A Ferrando; Steven D Levin; Yan Geng; Harald von Boehmer; Piotr Sicinski
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

View more
  27 in total

Review 1.  Role of the mammalian target of rapamycin pathway in lentiviral vector transduction of hematopoietic stem cells.

Authors:  Cathy X Wang; Bruce E Torbett
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

2.  Defining the Domain Arrangement of the Mammalian Target of Rapamycin Complex Component Rictor Protein.

Authors:  Ping Zhou; Ning Zhang; Ruth Nussinov; Buyong Ma
Journal:  J Comput Biol       Date:  2015-07-15       Impact factor: 1.479

3.  In vivo, Argonaute-bound microRNAs exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA.

Authors:  Gaspare La Rocca; Scott H Olejniczak; Alvaro J González; Daniel Briskin; Joana A Vidigal; Lee Spraggon; Raymond G DeMatteo; Megan R Radler; Tullia Lindsten; Andrea Ventura; Thomas Tuschl; Christina S Leslie; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-07       Impact factor: 11.205

Review 4.  mTOR and metabolic regulation of conventional and regulatory T cells.

Authors:  Chaohong Liu; Nicole M Chapman; Peer W F Karmaus; Hu Zeng; Hongbo Chi
Journal:  J Leukoc Biol       Date:  2015-02-24       Impact factor: 4.962

5.  Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.

Authors:  Y Fang; Y Yang; C Hua; S Xu; M Zhou; H Guo; N Wang; X Zhao; L Huang; F Yu; H Cheng; M L Wang; L Meng; T Cheng; W Yuan; D Ma; J Zhou
Journal:  Leukemia       Date:  2016-08-08       Impact factor: 11.528

6.  mTORC2 in Thymic Epithelial Cells Controls Thymopoiesis and T Cell Development.

Authors:  Hong-Xia Wang; Joyce S Cheng; Shuai Chu; Yu-Rong Qiu; Xiao-Ping Zhong
Journal:  J Immunol       Date:  2016-05-27       Impact factor: 5.422

7.  Metabolic signaling directs the reciprocal lineage decisions of αβ and γδ T cells.

Authors:  Kai Yang; Daniel Bastardo Blanco; Xiang Chen; Pradyot Dash; Geoffrey Neale; Celeste Rosencrance; John Easton; Wenan Chen; Changde Cheng; Yogesh Dhungana; Anil Kc; Walid Awad; Xi-Zhi J Guo; Paul G Thomas; Hongbo Chi
Journal:  Sci Immunol       Date:  2018-07-06

Review 8.  mTOR signaling, Tregs and immune modulation.

Authors:  Nicole M Chapman; Hongbo Chi
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

9.  PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.

Authors:  James T Lim; Neha Singh; Libia A Leuvano; Valerie S Calvert; Emanuel F Petricoin; David T Teachey; Richard B Lock; Megha Padi; Andrew S Kraft; Sathish K R Padi
Journal:  Mol Cancer Ther       Date:  2020-08-04       Impact factor: 6.261

Review 10.  mTORC signaling in hematopoiesis.

Authors:  Xiaomin Wang; Yajing Chu; Weili Wang; Weiping Yuan
Journal:  Int J Hematol       Date:  2016-01-20       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.